>
Switch to:

Myovant Sciences Inventory-to-Revenue

: 0.12 (As of Mar. 2022)
View and export this data going back to 2016. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Myovant Sciences's Total Inventories for the quarter that ended in Mar. 2022 was $7.2 Mil. Myovant Sciences's Revenue for the three months ended in Mar. 2022 was $57.6 Mil. Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.12.

Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Mar. 2022 increased from Dec. 2021 (0.12) to Dec. 2021 (0.12)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Myovant Sciences's Days Inventory for the three months ended in Mar. 2022 was 36.83.

Total Inventories can be measured by Days Sales of Inventory (DSI). Myovant Sciences's days sales of inventory (DSI) for the three months ended in Mar. 2022 was 11.35.

Inventory Turnover measures how fast the company turns over its inventory within a year. Myovant Sciences's Inventory Turnover for the quarter that ended in Mar. 2022 was 2.48.


Myovant Sciences Inventory-to-Revenue Historical Data

The historical data trend for Myovant Sciences's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Inventory-to-Revenue
Premium Member Only Premium Member Only - - - 0.04 0.02

Myovant Sciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Inventory-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.08 0.07 0.12 0.12

Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Inventory-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Inventory-to-Revenue falls into.



Myovant Sciences Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Myovant Sciences's Inventory-to-Revenue for the fiscal year that ended in Mar. 2022 is calculated as

Inventory-to-Revenue (A: Mar. 2022 )
=Total Inventories / Revenue
=( (Total Inventories (A: Mar. 2021 ) + Total Inventories (A: Mar. 2022 )) / count ) / Revenue (A: Mar. 2022 )
=( (2.611 + 7.584) / 2 ) / 230.972
=5.0975 / 230.972
=0.02

Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Mar. 2022 is calculated as

Inventory-to-Revenue (Q: Mar. 2022 )
=Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2021 ) + Total Inventories (Q: Mar. 2022 )) / count ) / Revenue (Q: Mar. 2022 )
=( (6.737 + 7.584) / 2 ) / 57.567
=7.1605 / 57.567
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences  (NYSE:MYOV) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Myovant Sciences's Days Inventory for the three months ended in Mar. 2022 is calculated as:

Days Inventory=Total Inventories (Q: Mar. 2022 )/Cost of Goods Sold (Q: Mar. 2022 )*Days in Period
=7.1605/17.742*365 / 4
=36.83

2. Total Inventories can be measured by Days Sales of Inventory (DSI).

Myovant Sciences's Days Sales of Inventory for the three months ended in Mar. 2022 is

Days Sales of Inventory (DSI)=Total Inventories (Q: Mar. 2022 )/Revenue (Q: Mar. 2022 )*Days in Period
=7.1605/57.567*365 / 4
=11.35

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Myovant Sciences's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2022 ) / Total Inventories (Q: Mar. 2022 )
=17.742 / 7.1605
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo officer: Chief Medical Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie director C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen director C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Seely Lynn director, officer: Principal Executive Officer 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025

Myovant Sciences Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)